Lack of correlation between different congestion markers in acute decompensated heart failure

Svenja Haag1,2 · Alexander Jobs1,2,3,4 · Thomas Stiermaier1,2 · Carlo-Federico Fichera1,2 · Christina Paitazoglou1,2 · Ingo Eitel1,2 · Steffen Desch1,2,3,4 · Holger Thiele3,4

Received: 9 January 2022 / Accepted: 3 May 2022 / Published online: 1 June 2022 © The Author(s) 2022

Abstract
Background Hospitalizations for acute decompensated heart failure (ADHF) are commonly associated with congestion-related signs and symptoms. Objective and quantitative markers of congestion have been identified, but there is limited knowledge regarding the correlation between these markers.
Methods Patients hospitalized for ADHF irrespective of left ventricular ejection fraction were included in a prospective registry. Assessment of congestion markers (e.g., NT-proBNP, maximum inferior vena cava diameter, dyspnea using visual analogue scale, and a clinical congestion score) was performed systematically on admission and at discharge. Telephone interviews were performed to assess clinical events, i.e., all-cause death or readmission for cardiovascular cause, after discharge. Missing values were handled by multiple imputation.
Results In total, 130 patients were prospectively enrolled. Median length of hospitalization was 9 days (interquartile range 6 to 16). All congestion markers declined from admission to discharge ( \( p < 0.001 \)). No correlation between the congestion markers could be identified, neither on admission nor at discharge. The composite endpoint of all-cause death or readmission for cardiovascular cause occurred in 46.2% of patients. Only NT-proBNP at discharge was predictive for this outcome (hazard ratio 1.48, 95% confidence interval 1.15 to 1.90, \( p = 0.002 \)).
Conclusion No correlation between quantitative congestion markers was observed. Only NT-proBNP at discharge was significantly associated with the composite endpoint of all-cause death or readmission for cardiovascular cause. Findings indicate that the studied congestion markers reflect different aspects of congestion.

Svenja Haag and Alexander Jobs contributed equally to this work.

alexander.jobs@medizin.uni-leipzig.de

1 Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Medical Clinic II, University Hospital Schleswig-Holstein, Lübeck, Germany
2 German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany
3 Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Strümpellstr. 39, 04289 Leipzig, Germany
4 Leipzig Heart Institute, Leipzig, Germany
Introduction

Heart failure is one of the most common causes for hospital admission in Western countries including Germany [1]. Most heart failure hospitalizations take place due to acute decompensated heart failure (ADHF) with de novo or worsening signs and/or symptoms of congestion [e.g., dyspnea, rales, jugular venous distension (JVD), and edema] [2]. Such hospitalizations have a major impact on the patient’s prognosis [3].

The clinical evaluation of patients with heart failure should include assessment for signs and symptoms associated with elevated ventricular filling pressures (“clinical congestion”). During in-hospital treatment, decongestion with the goal to achieve euvolemia is a major task for treating physicians. While signs and symptoms apparently improve during in-hospital treatment, residual signs of congestion at time of discharge predict rehospitalization and mortality remains unacceptably high after discharge. This raises the question, whether optimal decongestion was achieved at discharge or not. A prerequisite to achieve optimal decongestion is the ability to assess congestion accurately. However, prediction of elevated cardiac filling pressures by single clinical signs of congestion has a rather moderate value. Invasive assessment and monitoring of hemodynamic congestion by means of pulmonary artery catheters failed to show a benefit in the ESCAPE trial [4]. Several non-invasive markers related to the congestion status have been studied afterwards. Among other markers, change in N-terminal pro-B-type natriuretic peptide (NT-proBNP), relief of dyspnea measured on a visual analogue scale (VAS), and the inferior vena cava (IVC) diameter have been identified to be associated with the risk for rehospitalization and/or mortality [5–7].

Based on these findings, the use of a multimodal approach to assess congestion status during decongestion treatment has recently been recommended [8, 9]. However, previous studies have analyzed the prognostic impact of only a single marker. Therefore, aim of this study was to assess the correlation between different non-invasive congestion markers measured on the continuous scale and to compare their impact on prognosis in patients hospitalized for ADHF.

Methods

Patient population

Patients admitted to the Department of Cardiology, Angiology and Intensive Care Medicine of the University Hospital Schleswig-Holstein due to ADHF irrespective of left ventricular ejection fraction were prospectively enrolled in a single center registry. ADHF was defined as heart failure-related functional limitation (New York Heart Association [NYHA] class ≥ II) and peripheral edema or pulmonary congestion (defined as either rales on lung auscultation or pulmonary congestion on chest X-ray). No specific exclusion criteria were applied. All patients provided written informed consent. The study was approved by the local ethics committee of the University of Lübeck and all patients gave written informed consent.
Congestion markers

Congestion was assessed at predefined visits using different non-invasive markers. More specific, we recorded clinical signs by physical examination, NT-proBNP, IVC diameters measured during focused echocardiography studies using a handheld device (Vscan Extend™, GE Healthcare, Chicago, Illinois, United States) at bedside, and dyspnea using a VAS at hospital admission and hospital discharge.

Bedside IVC measurements were performed as recommended in current echocardiography guidelines. In short, the IVC was visualized in the subcostal view and measured just before the entrance of hepatic veins. IVC\textsubscript{max} is defined as the maximum diameter at end-expiration \cite{10}. Dyspnea was assessed using a 10 cm VAS. Patients marked their degree of dyspnea on the DVAS (0 cm = no dyspnea; 10 cm = worst imaginable dyspnea). A clinical congestion score incorporated several clinical congestion signs (Table 1) similar to the EVEREST congestion score whose elevated values are significantly associated to an increased risk of all-cause-mortality and heart failure hospitalization \cite{11}.

Follow-up and outcome

Follow-up visits were performed at 180 and 360 days after discharge by means of structured telephone interviews. The primary endpoint was the composite of all-cause death or readmission for cardiovascular cause. Length of hospital stay was analyzed as secondary endpoint.

Statistical analyses

We calculated summary statistics for patient characteristics and outcomes stratified by the occurrence of a primary endpoint event as median with interquartile range (IQR) for continuous variables and frequencies with percentages for categorical variables. Group differences were tested using Kruskal–Wallis or Chi-square tests, respectively. All congestion markers are continuous and at least ordinal. We assumed monotonic relations between each pair of congestion markers. Therefore, Spearman’s correlation coefficients were calculated to assess the degree of correlation between pairs of congestion markers. Cox regression analyses were performed to study the association of continuous congestion markers with the primary endpoint. In addition to univariable models, multivariable models considering all congestion markers were created to identify independent predictors.

Linear regression analyses were performed to study the association of continuous congestion markers with the length of hospital stay. Length of hospital stay and NT-proBNP were relatively skewed and therefore log-transformed for statistical analyses. Missing data were handled with multiple imputation using chained equations (number of imputations = 5). All analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria).

Results

In total, 130 patients were prospectively enrolled from November/2016 to September/2019. Baseline characteristics of the study population by outcome status are shown in Table 2. Patients with an outcome event during follow-up were older than patients without an outcome event (83 [IQR 76; 86] years versus 78 [IQR 70; 85] years, \(p = 0.021\)). However, other baseline characteristics including medical history and echocardiography findings did not differ between both the groups.

Trajectory of and correlation between congestion markers

Measures of all objective congestion markers declined over the course of in-hospital treatment (Fig. 1). Neither on hospital admission nor at hospital discharge did objective congestion markers correlate with each other as shown by visual inspection of scatterplots and correlation analyses (Table 3 and Fig. 2). NT-proBNP was not different at admission (3966 [IQR 2311; 7087] ng/l versus 4040 [2087; 8638] ng) nor at discharge.

The clinical congestion score is the sum of the degree of congestion in each domain. The degree of congestion in each domain is rated as follows: edema: 0 = none edema, 1 + = few (ankle or shank edema), 2 + = moderate (ankle and shank edema), 3 + = severe (peripheral edema up to anasarca); rales: 0 = no rales present in pulmonary auscultation, < 1/3 = moist rales present in the lower 1/3 of one or both lungs in pulmonary auscultation, 1/3–2/3 = moist rales present in the lower 1/3 up to lower 2/3 of one or both lungs in pulmonary auscultation, > 2/3 = present of moist rales all over both lungs during pulmonary auscultation; jugular venous pressure (JVP): < 6 cmH\textsubscript{2}O = absence of jugular venous distension (JVD) above the clavicle and no hepatojugular reflux (HJR), 6–10 cmH\textsubscript{2}O = JVD less than 4 cm above the clavicle and at most mild enlargement with HJR, > 10 cmH\textsubscript{2}O = JVD ≥ 4 cm above the clavicle and considerable enlargement with HJR.

Table 1: Clinical congestion score

| Signs   | Points |
|---------|--------|
| JVP     |        |
| < 6 cmH\textsubscript{2}O | 0 |
| 6–10 cmH\textsubscript{2}O | 1 |
| > 10 cmH\textsubscript{2}O | 2 |
| Rales   |        |
| none    | 0 |
| < 1/3   | 1 |
| 1/3–2/3 | 2 |
| > 2/3   | 3 |
| Edema   |        |
| 0       | 1 + |
| 1       | 2 + |
| 2       | 3 + |

The clinical congestion score is the sum of the degree of congestion in each domain. The degree of congestion in each domain is rated as follows: edema: 0 = none edema, 1 + = few (ankle or shank edema), 2 + = moderate (ankle and shank edema), 3 + = severe (peripheral edema up to anasarca); rales: 0 = no rales present in pulmonary auscultation, < 1/3 = moist rales present in the lower 1/3 of one or both lungs in pulmonary auscultation, 1/3–2/3 = moist rales present in the lower 1/3 up to lower 2/3 of one or both lungs in pulmonary auscultation, > 2/3 = present of moist rales all over both lungs during pulmonary auscultation; jugular venous pressure (JVP): < 6 cmH\textsubscript{2}O = absence of jugular venous distension (JVD) above the clavicle and no hepatojugular reflux (HJR), 6–10 cmH\textsubscript{2}O = JVD less than 4 cm above the clavicle and at most mild enlargement with HJR, > 10 cmH\textsubscript{2}O = JVD ≥ 4 cm above the clavicle and considerable enlargement with HJR.
(2116 [1024; 4340] ng/l versus 2136 [813; 4925] ng) between patients with and without atrial fibrillation.

**Congestion markers and length of hospital stay**

Length of hospital stay was in median 9 days (IQR 6 to 16 days). Length of hospital stay did not differ between patients with and without a primary outcome event (P = 0.58 by Wilcoxon rank sum test). Of the congestion markers, only the clinical congestion score and IVCmax at baseline were significantly associated with length of hospital stay (Online Table 1).

**Congestion markers and the combined risk for death or readmission**

During the median follow-up of 188 (IQR 57–212) days, 60 of 130 (46.2%) patients suffered the composite primary outcome event of all-cause death or hospital readmission for cardiovascular cause. In total, 34 of 130 (26.2%) patients died during follow-up.

In clinical routine, severity of heart failure is generally assessed using the NYHA classification and severity of congestion by clinical signs and symptoms. Neither at admission nor at discharge did the NYHA class differ

---

**Table 2** Patient characteristics

|                               | All patients n = 130 | Patients without event n = 70 | Patients with event n = 60 | p-value |
|-------------------------------|----------------------|-------------------------------|----------------------------|---------|
| Age, years                    | 80 [73;85]           | 78 [70;85]                    | 83 [76;86]                 | 0.021   |
| Female sex                    | 41 (31.5%)           | 23 (32.9%)                    | 18 (30.0%)                 | 0.873   |
| BMI, kg/m²                    | 28.5 [25.7;32.1]     | 28.9 [26.4;32.9]              | 28.0 [25.5;31.2]           | 0.231   |
| SBP, mmHg                     | 132 [120;150]        | 130 [120;153]                 | 132 [120;150]              | 0.578   |
| Pulse, min⁻¹                  | 83 [70-99]           | 83 [72-101]                   | 82 [65-98]                 | 0.482   |
| eGFR, ml/min/1.73 m²          | 52 [39;65]           | 52 [43;70]                    | 50 [37;61]                 | 0.091   |
| Comorbidities and medical history |                     |                               |                            |         |
| Atrial fibrillation           | 64 (49.2%)           | 35 (50.0%)                    | 29 (48.3%)                 | 0.989   |
| Ischemic heart disease        | 70 (53.8%)           | 35 (50.0%)                    | 35 (58.3%)                 | 0.439   |
| PCI                            | 55 (42.3%)           | 27 (38.6%)                    | 28 (46.7%)                 | 0.451   |
| CABG                           | 29 (22.9%)           | 13 (18.6%)                    | 16 (26.7%)                 | 0.371   |
| Anemia                         | 70 (53.8%)           | 34 (48.6%)                    | 36 (60.0%)                 | 0.260   |
| Hyponatremia                   | 16 (12.3%)           | 9 (12.9%)                     | 7 (11.7%)                  | > 0.99  |
| Echocardiography              |                      |                               |                            |         |
| LVEF                           | 61 (46.9%)           | 30 (42.9%)                    | 31 (51.7%)                 | 0.408   |
| EF, %                          | 40 [30;53]           | 40 [30;53]                    | 38 [30;51]                 | 0.250   |
| Mitral regurgitation           |                      |                               |                            | 0.406   |
| None                           | 27 (20.8%)           | 17 (24.3%)                    | 10 (16.7%)                 |         |
| I                              | 47 (36.2%)           | 21 (30.0%)                    | 26 (43.3%)                 |         |
| II                             | 39 (30.0%)           | 23 (32.9%)                    | 16 (26.7%)                 |         |
| III                            | 17 (13.1%)           | 9 (12.9%)                     | 8 (13.3%)                  |         |
| Tricuspid regurgitation        |                      |                               |                            | 0.753   |
| None                           | 28 (21.5%)           | 17 (24.3%)                    | 11 (18.3%)                 |         |
| I                              | 38 (29.2%)           | 21 (30.0%)                    | 17 (28.3%)                 |         |
| II                             | 36 (27.7%)           | 19 (27.1%)                    | 17 (28.3%)                 |         |
| III                            | 28 (21.5%)           | 13 (18.6%)                    | 15 (25.0%)                 |         |

Patient characteristics based on the first imputed dataset. Values are median (interquartile range) or number of patients (%). Anemia was defined according to the World Health Organization as hemoglobin levels < 12.0 g/dl in women and < 13.0 g/dl in men. Hyponatremia was defined as sodium levels < 135 mmol/l. BMI body mass index, CABG coronary artery bypass graft, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, SBP systolic blood pressure.
between patients with and without an outcome event in our study population (Table 4). Likewise, no recorded measure of congestion differed between patients with and without an outcome event at admission. However, patients with an outcome event had more severe congestion as measured by the clinical congestion score and NT-proBNP at discharge (Table 4).

None of the congestion markers measured at admission was associated with the primary outcome (Table 5). Higher NT-proBNP levels at discharge were, however, predictive for a primary outcome event during follow-up. Dichotomizing discharge NT-proBNP values revealed that an NT-proBNP level < 1.500 ng/l was also associated with better outcome in our study population (Table 5).

Fig. 1 Scatter plots with overlaying jitter plots visualizing the distribution of congestion markers on admission and at discharge. Red points indicate measurements based on observed data and blue points indicate measurements based on imputed data. N-terminal pro-B-type natriuretic peptide (NT-proBNP), maximum inferior vena cava diameter (IVCmax), dyspnea as visual analogue scale (VAS), and the clinical congestion score declined from admission to discharge as visualized by the location of the majority of point in the lower right part of the plots (P < 0.001 for all by Wilcoxon signed rank test)
### Table 3 Congestion on admission and at discharge

|                      | All patients (n = 130) | Patients without event (n = 70) | Patients with event (n = 60) | p-value |
|----------------------|------------------------|---------------------------------|-----------------------------|---------|
| **Admission**        |                        |                                 |                             |         |
| NYHA class           |                        |                                 |                             | 0.839   |
| II                   | 4 (3.08%)              | 2 (2.86%)                       | 2 (3.33%)                   |         |
| III                  | 84 (64.6%)             | 47 (67.1%)                      | 37 (61.7%)                  |         |
| IV                   | 42 (32.3%)             | 21 (30.0%)                      | 21 (35.0%)                  |         |
| Rales                |                        |                                 |                             | 0.281   |
| Absent              | 23 (17.7%)             | 15 (21.4%)                      | 8 (13.3%)                   |         |
| < 1/3                | 70 (53.8%)             | 33 (47.1%)                      | 37 (61.7%)                  |         |
| 1/3–2/3             | 36 (27.7%)             | 21 (30.0%)                      | 15 (25.0%)                  |         |
| > 2/3               | 1 (0.77%)              | 1 (1.43%)                       | 0 (0.00%)                   |         |
| Edema                |                        |                                 |                             | 0.205   |
| Absent              | 4 (3.08%)              | 4 (5.71%)                       | 0 (0.00%)                   |         |
| 1+                  | 32 (24.6%)             | 17 (24.3%)                      | 15 (25.0%)                  |         |
| 2+                  | 54 (41.5%)             | 31 (44.3%)                      | 23 (38.3%)                  |         |
| 3+                  | 40 (30.8%)             | 18 (25.7%)                      | 22 (36.7%)                  |         |
| Jugular venous pressure |                    |                                 |                             | 0.815   |
| < 6 cm H₂O          | 35 (26.9%)             | 19 (27.1%)                      | 16 (26.7%)                  |         |
| 6–10 cm H₂O         | 20 (15.4%)             | 12 (17.1%)                      | 8 (13.3%)                   |         |
| > 10 cm H₂O         | 75 (57.7%)             | 39 (55.7%)                      | 36 (60.0%)                  |         |
| Congestion score    | 5.00 [4.00;5.75]       | 4.00 [3.00;6.00]                | 5.00 [4.00;5.00]            | 0.481   |
| IVCmax, mm          | 25 [23;29]             | 25 [23;27]                      | 25 [23;29]                  | 0.276   |
| DVAS, cm            | 5.6 [3.7;7.5]          | 5.5 [4.3;7.5]                   | 5.8 [2.5;7.5]               | 0.848   |
| NT-proBNP, ng/l     | 4011 [2103;8107]       | 3904 [2103;6981]                | 4585 [2132;9528]            | 0.422   |
| **Discharge**       |                        |                                 |                             |         |
| NYHA class           |                        |                                 |                             | 0.571   |
| I                   | 30 (23.1%)             | 17 (24.3%)                      | 13 (21.7%)                  |         |
| II                  | 61 (46.9%)             | 35 (50.0%)                      | 26 (43.3%)                  |         |
| III                 | 35 (26.9%)             | 17 (24.3%)                      | 18 (30.0%)                  |         |
| IV                  | 4 (3.08%)              | 1 (1.43%)                       | 3 (5.00%)                   |         |
| Rales                |                        |                                 |                             | 0.463   |
| Absent              | 100 (76.9%)            | 56 (80.0%)                      | 44 (73.3%)                  |         |
| < 1/3               | 21 (16.2%)             | 11 (15.7%)                      | 10 (16.7%)                  |         |
| 1/3–2/3             | 9 (6.92%)              | 3 (4.29%)                       | 6 (10.0%)                   |         |
| Edema                |                        |                                 |                             | 0.264   |
| Absent              | 77 (59.2%)             | 46 (65.7%)                      | 31 (51.7%)                  |         |
| 1+                  | 43 (33.1%)             | 20 (28.6%)                      | 23 (38.3%)                  |         |
| 2+                  | 10 (7.69%)             | 4 (5.71%)                       | 6 (10.0%)                   |         |
| Jugular venous pressure |                    |                                 |                             | 0.320   |
| < 6 cm H₂O          | 94 (72.3%)             | 53 (75.7%)                      | 41 (68.3%)                  |         |
| 6–10 cm H₂O         | 12 (9.23%)             | 4 (5.71%)                       | 8 (13.3%)                   |         |
| > 10 cm H₂O         | 24 (18.5%)             | 13 (18.6%)                      | 11 (18.3%)                  |         |
| Congestion score    | 1.00 [0.00;2.00]       | 1.00 [0.00;2.00]                | 1.00 [0.75;2.00]            | 0.011   |
| IVCmax, mm          | 21 [19;26]             | 21 [19;25]                      | 21 [19;27]                  | 0.404   |
| DVAS, cm            | 1.8 [0.4;3.0]          | 1.8 [0.5;2.7]                   | 1.7 [0.1;3.3]               | 0.903   |
| NT-proBNP, ng/l     | 2160 [988;5283]        | 1826 [794;3291]                 | 2992 [1707;7352]            | 0.002   |

Congestion markers on admission and at baseline based on the first imputed dataset. Values are median (interquartile range) or number of patients (%). IVCmax maximum inferior vena cava diameter, NT-proBNP N-terminal pro–B-type natriuretic peptide, NYHA New York Heart Association, DVAS visual analogue scale for dyspnea.
Considering all congestion markers in a multivariable model identified only NT-proBNP at discharge as independent predictor for the primary clinical outcome. This finding was true for continuously coded as well as dichotomized congestion marker variables (Table 5).

In line with this, the multivariable model considering all congestion markers measured at discharge did not predict the primary outcome better than a univariable model considering only the NT-proBNP level at discharge. Again, this finding was persistent for continuously coded as well as dichotomized congestion marker variables (Table 5).

Fig. 2 Scatter plots visualizing correlations between congestion markers on admission: a N-terminal pro-B-type natriuretic peptide (NT-proBNP) versus maximum inferior vena cava diameter (IVC-max); b dyspnea as visual analogue scale (VAS) versus IVC-max; c NT-proBNP versus dyspnea as VAS. Red points indicate measurements based on observed data and blue points indicate measurements of which at least one value was imputed. Box plots summarize distribution of the corresponding congestion marker.
The main findings of our study are as follows: (1) the investigated non-invasive congestion markers do not correlate with each other and (2) NT-proBNP levels may predict outcome after ADHF hospitalization.

ADHF is a sentinel event in patients with chronic heart failure because the mortality risk considerably increases after such hospitalization. Hospital presentation is generally triggered after rise of clinical signs and symptoms of congestion above a bearable level. This clinical manifestation (i.e., clinical congestion) of elevated filling pressures is, however, the only visible part during clinical examination. Detection of clinical congestion can be challenging, crude, and operator-dependent. While no sign has perfect predictive value, signs of congestion in aggregate are useful to understanding the hemodynamic status and can inform treatment decisions. In patients without or after resolution of typical signs of congestion, elevated cardiac filling pressures (i.e., hemodynamic congestion) and elevated pressure in the venous system may persists. Previous studies found that filling pressures start to rise days to weeks before hospital presentation for ADHF [12]. Sensitivity and specificity of clinical signs and symptoms to detect hemodynamic congestion are low [13, 14]. Therefore, invasive measurement of right atrial pressure and pulmonary capillary wedge pressure (PCWP) by means of pulmonary artery catheterization remain the reference standard for evaluation of hemodynamic congestion [15]. However, this invasive monitoring is technically demanding, prone to complications, and did not improve outcome in the ESCAPE trial with pulmonary artery catheters being in place only for a median of 1.9 days [4]. As a result, the optimal approach to assess congestion and guide treatment

| Table 4 | Correlation between congestion markers on admission and at discharge |
|---------|---------------------------------------------------------------|
|         | CS | IVCmax | VAS | NT-proBNP |
| Hospital admission |
| CS      | 0.09 (−0.08 to 0.26) | 0.04 (−0.14 to 0.22) | −0.07 (−0.24 to 0.101) |
| IVCmax  | 0.11 (−0.07 to 0.28) | 0.04 (−0.13 to 0.22) |
| VAS     | 0.11 (−0.07 to 0.28) | 0.04 (−0.13 to 0.22) |
| NT-proBNP | −0.07 (−0.24 to 0.101) | −0.09 (−0.25 to 0.09) | 0.04 (−0.13 to 0.22) |

| Hospital discharge |
| CS      | 0.17 (−0.01 to 0.34) | 0.02 (−0.16 to 0.2) | 0.17 (−0.02 to 0.347) |
| IVCmax  | 0.12 (−0.06 to 0.29) | 0.05 (−0.13 to 0.24) |
| VAS     | 0.12 (−0.06 to 0.29) | 0.05 (−0.13 to 0.23) |
| NT-proBNP | 0.05 (−0.13 to 0.24) | 0.05 (−0.13 to 0.23) |

Spearman correlation coefficients and respective 95% confidence intervals for congestion marker measures at hospital admission and at hospital discharge based on multiple imputed data. CS clinical congestion score, IVCmax maximum inferior vena cava diameter, NT-proBNP N-terminal pro-B-type natriuretic peptide, DVAS visual analogue scale for dyspnea.

| Table 5 | Association of congestion markers with clinical outcome |
|---------|-----------------------------------------------------|
|         | HR (95% CI) | P | FMI |
| Admission |
| **Univariable models** |
| NT-proBNP, per ln ng/l | 1.09 (0.83–1.42) | 0.534 | 0 |
| IVCmax, per mm | 1.03 (0.97–1.09) | 0.373 | 0.005 |
| CS, per point | 1.11 (0.94–1.32) | 0.223 | 0.005 |
| DVAS, per cm | 0.95 (0.86–1.05) | 0.332 | 0.025 |
| DVAS < median | 0.96 (0.57–1.61) | 0.876 | 0.021 |
| Discharge |
| **Univariable models** |
| NT-proBNP, per ln | 1.48 (1.15–1.90) | 0.002 | 0.170 |
| NT-proBNP < 1,500 ng/l | 0.45 (0.22–0.91) | 0.026 | 0.168 |
| IVCmax, per mm | 1.01 (0.96–1.06) | 0.627 | 0.029 |
| CS, per point | 1.17 (0.97–1.4) | 0.093 | 0.144 |
| CS < 2 points | 0.63 (0.36–1.11) | 0.112 | 0.165 |
| DVAS, per cm | 0.97 (0.85–1.11) | 0.645 | 0.009 |
| DVAS < median | 1.14 (0.67–1.92) | 0.628 | 0.023 |
| **Multivariable models** |
| NT-proBNP, per ln | 1.47 (1.13–1.90) | 0.004 | 0.188 |
| + IVCmax, per mm | 1.00 (0.95–1.06) | 0.915 | 0.097 |
| + CS, per point | 1.13 (0.93–1.37) | 0.235 | 0.199 |
| + DVAS, per cm | 0.96 (0.83–1.10) | 0.529 | 0.012 |
| NT-proBNP < 1,500 ng/l | 0.45 (0.22–0.91) | 0.027 | 0.166 |
| + IVCmax < 21 mm | 1.03 (0.61–1.76) | 0.899 | 0.058 |
| + CS < 2 points | 0.64 (0.36–1.14) | 0.128 | 0.190 |
| + DVAS < median | 1.09 (0.64–1.84) | 0.757 | 0.013 |

Risk for all-cause death or readmission for cardiovascular cause depending on the degree of congestion as measured by quantitative congestion markers. CI confidence interval, CS clinical congestion score, FMI fraction of missing information, HR hazard ratio, IVCmax maximum inferior vena cava diameter, NT-proBNP N-terminal pro-B-type natriuretic peptide, DVAS visual analogue scale for dyspnea.

**Discussion**

The main findings of our study are as follows: (1) the investigated non-invasive congestion markers do not correlate with each other and (2) NT-proBNP levels may predict outcome after ADHF hospitalization.

ADHF is a sentinel event in patients with chronic heart failure because the mortality risk considerably increases after such hospitalization. Hospital presentation is generally triggered after rise of clinical signs and symptoms of congestion above a bearable level. This clinical manifestation (i.e., clinical congestion) of elevated filling pressures is, however, the only visible part during clinical examination. Detection of clinical congestion can be challenging, crude, and operator-dependent. While no sign has perfect predictive value, signs of congestion in aggregate are useful to understanding the hemodynamic status and can inform treatment decisions. In patients without or after resolution of typical signs of congestion, elevated cardiac filling pressures (i.e., hemodynamic congestion) and elevated pressure in the venous system may persists. Previous studies found that filling pressures start to rise days to weeks before hospital presentation for ADHF [12]. Sensitivity and specificity of clinical signs and symptoms to detect hemodynamic congestion are low [13, 14]. Therefore, invasive measurement of right atrial pressure and pulmonary capillary wedge pressure (PCWP) by means of pulmonary artery catheterization remain the reference standard for evaluation of hemodynamic congestion [15].
during hospitalization for ADHF remains unknown and challenging. This is why non-invasive congestion markers such as NT-proBNP, IVC diameters, B-lines in lung ultrasound, thoracic impedance, and intra-abdominal pressure have been examined in terms of their prognostic relevance in recent years. For example, patients with chronic heart failure free of clinical signs of congestion and only mild symptoms (i.e., NYHA ≤ II) often had evidence of congestion on ultrasound in an observational study. These patients were at risk for clinical events, highlighting the importance of sub-clinical congestion [16, 17].

We assessed NT-proBNP, IVCmax, DVAS, and clinical congestion signs in patients enrolled in a prospective ADHF registry. All these congestion markers individually have been proven to be of prognostic importance in previous studies [5, 6, 18–22]. However, correlations between these markers and their relative prognostic importance compared to each other are largely unknown. Despite missing prospective studies, recently published position papers recommend a multi-parameter-based approach to evaluate decongestion and to avoid early readmission [8, 9].

Each congestion marker has specific advantages and limitations. NT-proBNP is the most thoroughly studied biomarker in heart failure. It is a quantitative marker and a strong independent predictor for death and readmission of cardiovascular cause in ADHF patients [7]. For example, a NT-proBNP level < 1,500 ng/l at discharge has previously been identified to signify a low risk of death in patients with ADHF [7]. Furthermore, NT-proBNP has a very high negative predictive value for ruling out ADHF as diagnosis in patients presenting with dyspnea [23]. However, guiding in-hospital treatment of ADHF patients based on NT-proBNP values failed to improve 6-month outcome in the PRIMA II trial [24]. In addition, increased NT-proBNP levels are non-specific for heart failure. Impaired renal function and pulmonary embolism are for example associated with elevated NT-proBNP-levels. Furthermore, cardiac distress, which occurs in sepsis or pulmonary disease, can lead to elevation of natriuretic peptides. Nevertheless, we found higher NT-proBNP values at discharge to be associated with a primary outcome event (death or cardiovascular hospitalization) in our study, supporting previous findings in a pooled analysis of ADHF registries [24]. However, NT-proBNP measured at admission was not predictive as previously shown for B-type natriuretic peptide in a post-hoc analysis of the VERITAS trial [25].

The IVC diameter can be used to estimate right atrial pressure semiquantitatively [10, 26]. After a short period of training, the IVC diameter can easily and reliably be determined even with a handheld ultrasound device at bedside [27–32]. However, visualization of the IVC may not be possible in around 15% of cases due to anatomical factors such as overweight or meteorism [33]. Other factors such as positive pressure ventilation, sex, and height may also influence the IVC diameter independently of the right atrial pressure [34–36]. Previous studies identified IVCmax measured at hospital admission as predictor for all-cause mortality in ADHF populations [18, 21]. However, we observed no association of IVCmax with the primary outcome of all-cause death or readmission for cardiovascular cause in our rather small collective. As suggested by the observations made for natriuretic peptides, the prognostic value of congestion markers might change, probably increase, with the time point of assessment during the course from admission to discharge of an ADHF hospitalization to the following chronic stable phase. Supporting this hypothesis, IVCmax has shown to be highly predictive for an adverse outcome in patients with chronic heart failure [21].

Dyspnea is one of the most common symptoms in ADHF and its relief is associated to the patient’s general well-being [37]. Furthermore, in post-hoc analyses of ASCEND-AHF (n = 7141 patients) and Pre-RELAX-AHF (n = 232 patients), it has been shown that dyspnea improvement may be a marker of decongestion and is associated with a better 30 day outcome [6, 38]. Dyspnea assessment by means of a DVAS is influenced by many factors, e.g., pulmonary comorbidities [38, 39]. In our population, the DVAS was not associated with the combined endpoint of all-cause death or readmission for cardiovascular cause.

Single signs of clinical congestion lack sensitivity as well as specificity of hemodynamic congestion [14]. Therefore, investigators combined several clinical congestion signs to congestion scores to improve the diagnostic value. For example, the EVEREST score was derived from the EVEREST trial population (2061 patients with LVEF < 40%, NYHA ≥ III, and two or more signs of volume overload) and was associated with an increased 30 day and all-cause mortality [11]. Combining clinical congestion signs to a clinical congestion score similar to the EVEREST score was not associated with the all-cause death or readmission for cardiovascular cause in our analysis. However, large-scale registry analysis of more than 120,000 patients has previously shown that the severity of peripheral edema at presentation is associated with mortality during the index hospitalization as well as during follow-up [40]. Novel methods like the near-infrared spectroscopy for the assessment of the right atrial pressure might offer more precise tools in the future as compared to the crude semi-quantitative bedside assessment of jugular vein distention [41]. Even though all studied markers are meant to be associated with congestion, we did not observe a statistical correlation between these continuous variables. Congestion was formally defined as elevated left ventricular end-diastolic pressure in the past [15]. However, volume overload—as a consequence of renal sodium and water retention with resulting expansion of plasma volume as well as extracellular interstitial water—plays an important
role in heart failure-related congestion [42]. The lack of correlation between NT-proBNP, IVCmax, DVAS, and the clinical congestion score is probably caused by the fact that each parameter measures different aspects of congestion [43]. The NT-proBNP concentration increases in response to stretch of the cardiac wall due to transmural pressure and volume overload [44], rendering it a good marker of intravascular congestion and hemodynamic congestion [45]. The IVC diameter is likewise a gauge of intravascular congestion but values of both parameters are modulated by different parameters. Dyspnea measured on the DVAS is secondary to tissue congestion of the lung and the clinical congestion scores combine measures of tissue as well as intravascular congestion. This highlights that the investigated markers are not interchangeable but probably complementary. The authors of a recent position paper recommend integration of the degree of congestion assessed by multiple markers to evaluate euvolemia/congestion before discharge [9, 17]. Our findings clearly support this recommendation. However, a multimodal approach like this has not been evaluated in a randomized controlled trial so far. Moreover, it is unclear whether congestion markers are only of prognostic value or can be used to guide decongestion with the goal of improving prognosis. First data of the ESCAPE trial and PRIMA II trial suggest that tailoring treatment on a single congestion marker may not be beneficial for patients [4, 24]. The results of the ongoing CAVA-ADHF trial will answer the question whether IVC diameter-guided decongestion improves the level of decongestion at discharge or not [46].

Limitations

Our study has several limitations that need to be acknowledged. First, all patients were enrolled in a prospective registry conducted in a single tertiary care academic medical center by a single investigator (SH) based on a standardized protocol, which may limit generalizability. Second, the analyzed population is relatively small, which may have an impact on the statistical power to detect significant correlations or outcome associations. However, the observed correlation coefficients are far from being significant which make it very unlikely that they would be relevantly different in a larger population.

Conclusion

We observed no correlation between the degrees of congestion assessed by different continuous congestion markers. Only NT-proBNP determined at discharge was significantly associated with the composite endpoint of all-cause death or readmission for cardiovascular cause. Our findings indicate that the studied congestion markers reflect different aspects of congestion. Therefore, using several congestion markers in an integrative approach as recently recommended might be beneficial. However, randomized controlled trials are necessary to assess whether such an approach would improve the outcome of ADHF patients.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00392-022-02036-9.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Neumann T, Biermann J, Erbel R, Neumann A, Wasem J, Ertl G, Dietz R (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtach Arztebl Int 106(16):269–275
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lam CSP, Lyon AR, McMurray JJV, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD (2021) 2021ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726
3. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA (2007) Candesartan in heart failure: assessment of reduction in M, morbidity I. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482–7
4. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, Investigators E, Coordinators ES (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13):1625–1633
5. Goonewardena SN, Gemignani A, Ronan A, Vasaivala S, Blair J, Brennan JM, Shah DP, Spencer KT (2008) Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission

 Springer
after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging 1(5):595–601
6. Metra M, Teerlink JR, Felker GM, Greenberg BH, Filippatos G, Ponikowski P, Teichman SL, Umenori E, Voors AA, Weatherley BD, Cotter G (2010) Dyspnea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 12(10):1130–1139
7. Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V, Damman P, Tijssen JG, Pinto YM (2014) A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on acute decompensated heart failure: ELAN-HF score. Heart 100(2):115–125
8. Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, Kenizou D, Maillier B, Nazeyrollas P, Roul G, Fillieux L, Abraham WT, Januzzi Jr J, Sebag L, Zannad F, Mebazaa A, Rossignol P, Ini-Crct GN, the EFHFG (2018) Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail 6(4):273–285
9. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion - a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail 21(2):137–155
10. Rudski LG, Lai WW, Afifalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of Echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr 23(7):685–713 (quiz 786-8)
11. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Tavner B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, Investigators ET (2013) Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur J Heart Fail 15(11):835–843
12. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shaville D, Jeffries B, Yadav JS, Group CTS (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658–66
13. Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, Califf RM, Nohria A (2008) Value of clinical assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 1(3):170–177
14. Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261(6):848–848
15. Gheorghiade M, Fiolath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Janouge G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G (2010) European society of C, European society of intensive care M. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine. Eur J Heart Fail 12(5):423–33
16. Pellicori P, Shah P, Cuthbert J, Urbiniat A, Zhang J, Kallvikbacka-Bennett A, Clark AL, Cleland JGF (2019) Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail 21(7):904–916
17. Pellicori P, Platze E, Daum J, Ter Maaten JM, Martens P, Pivetta EA, Cleland JGF, McMurray JFV, Mullens W, Solomon SD, Zannad F, Gargani L, Girerd N (2021) Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail 23(5):703–712
18. Jobs A, Brunjes K, Katalinic A, Babaev V, Desch S, Reppel M, Thiele H (2017) Inferior vena cava diameter in acute decompensated heart failure as predictor of all-cause mortality. Heart Vessels 32(7):856–864
19. Lee HF, Hsu LA, Chang CJ, Chan YH, Wang CL, Ho WJ, Chu PH (2014) Prognostic significance of dilated inferior vena cava in advanced decompensated heart failure. Int J Cardiovasc Imaging 30(7):1289–1295
20. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW (2000) Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am J Heart 140(6):840–847
21. Pellicori P, Carubelli V, Zhang J, Castellio T, Sherw N, Clark AL, Cleland JG (2013) IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6(1):16–28
22. Santaguida PL, Don-Wauchope AC, Oremus M, McKeilvie R, Ali U, Hill SA, Balion C, Booth RA, Brown JA, Bustamam A, Sohel N, Raina P (2014) BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 19(4):453–470
23. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Iordain P, Komajda M, Liu PP, Donoghah T, McDonald D, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10(9):824–839
24. Stienen S, Salah K, Moans AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, Bayes-Genis A, Tijssen JG, Pinto YM, Kok WE (2018) NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation 137(16):1671–1683
25. Cleland JG, Teerlink JR, Davison JF, Shaw JA, Metra M, Senger S, Milo O, Cotter G, Bourge RC, Parker JD, Janouge A, Krum H, O’Connor CM, Torre-Amione G, van Veldhuisen DJ, McMurray JFV, Investigators V (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure does it add useful prognostic information? An analysis of the value of endothelin receptor inhibition with tezosentan in acute heart failure studies (VERITAS). Eur J Heart Fail 19(6):739–747
26. Beigel R, Cereck B, Luo H, Siegel RJ (2013) Noninvasive evaluation of right atrial pressure. J Am Soc Echocardiogr 26(9):1033–1042
27. Andersson GN, Haugen BO, Graven T, Salvesen O, Mjolstad OC, Dalen H (2011) Feasibility and reliability of point-of-care pocket-sized echocardiography. Eur J Echocardiogr 12(9):665–670
28. Blair JE, Brennan JM, Goonewardena SN, Shah D, Vasaiwala S, Spencer KT (2009) Usefulness of hand-carried ultrasound to predict elevated left ventricular filling pressure. Am J Cardiol 103(2):246–247
29. Bustam A, Noor Azhar M, Singh Veriah R, Arumugam K, Loch A (2014) Performance of emergency physicians in point-of-care echocardiography following limited training. Emerg Med J 31(5):369–373
30. Dalen H, Gundersen GH, Skjetne K, Haug HH, Kleinau JO, Norekval TM, Graven T (2015) Feasibility and reliability of pocket-size ultrasound examinations of the pleural cavities and vena cava inferior performed by nurses in an outpatient heart failure clinic. Eur J Cardiovasc Nurs 14(4):286–293
31. Fields JM, Lee PA, Jenq KY, Mark DG, Panebianco NL, Dean AJ (2011) The interrater reliability of inferior vena cava ultrasound by bedside clinician sonographers in emergency department patients. Acad Emerg Med 18(1):98–101
32. Vourvouri EC, Schinkel AF, Roelandt JR, Boomsma F, Sianos G, Bounitoukos M, Sozzi FB, Rizzello V, Bax JJ, Karvounis HI, Poldermans D (2003) Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail 5(6):767–774
33. Ducat A, Zogheib E, Guinot P, Levy F, Trojette F, Diouf M, Slama M, Dupont H (2014) The gray zone of the qualitative assessment of respiratory changes in inferior vena cava diameter in ICU patients. Crit Care 18(1):R14
34. Guo J, Guo J, Feng F, Jiang D, Xu A, Yang F, Chen Q, Lin Y (2015) Impact of individual characteristics on sonographic IVC diameter and the IVC diameter/aorta diameter index. Am J Emerg Med 33(11):1602–1605
35. Taniguchi T, Ohtani T, Nakatani S, Hayashi K, Yamaguchi O, Komuro I, Sakata Y (2015) Impact of body size on inferior vena cava parameters for estimating right atrial pressure: a need for standardization? J Am Soc Echocardiogr 28(12):1420–1427
36. Via G, Tavazzi G, Price S (2016) Ten situations where inferior vena cava ultrasound may fail to accurately predict fluid responsiveness: a physiologically baseded point of view. Intensive Care Med 42(7):1164–1167
37. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Cas LD, Kremastinos DT, O’Connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ (2008) Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 14(9):777–784
38. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O’Connor CM, Ponikowski P (2013) Predictors of early dyspnea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 15(4):456–464
39. Hendren NS, Dranzer MH, Pandey A, Tang WHH, Grodin JL (2019) Implications of perceived dyspnea and global well-being measured by visual assessment scales during treatment for acute decompensated heart failure. Am J Cardiol 124(3):402–408
40. Shoaib A, Mamas MA, Ahmad Q, McDonagh TM, Hardman SMC, Rashid M, Butler R, Duckett S, Satchithananda D, Nolan J, Dargie HJ, Clark AL, Cleland JGF (2019) Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. Int J Cardiol 285:40–46
41. Pellicori P, Clark AL, Kallvikbacka-Bennett A, Zhang J, Urbinati A, Monzo L, Dierckx R, Anker SD, Cleland JGF (2017) Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study. Eur J Heart Fail 19(7):883–892
42. Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JIV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, Bauer-sachs J (2021) The struggle towards a universal definition of heart failure-how to proceed? Eur Heart J 42(24):2331–2343
43. Miller WL (2016) Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail 9(8):e002922
44. Fu S, Ping P, Wang F, Luo L (2018) Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng 12:2
45. Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, Burkhoff D, Zannad F, Udelson JE, Voors AA (2020) Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17(10):641–655
46. Jobs A, Vonthein R, Konig IR, Schafer J, Nauck M, Haag S, Fichera CF, Stiermaier T, Ledwoch J, Schneider A, Valentova M, von Haehling S, Stork S, Westermann D, Lenz T, Arnold N, Edelmann F, Seppelt P, Felix S, Lutz M, Hedwig F, Borggrefe M, Scherer C, Desch S, Thiele H (2020) Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF-DZHK10 trial. ESC Heart Fail 7(3):973–983